Wave’s OLE phase has just begun. This open-label multicenter trial aims to evaluate WVE-210201 in boys with Duchenne muscular dystrophy previously included in WVE-DMDX51-001, who were eligible for exon 51 skip. The first I-Motion patient was screened on January 7th.
Still in Duchenne muscular dystrophy, the first patient of the institute was screened just before the holidays in the Anti-myostatin study. Also known as Spitfire, this double-blind, placebo-controlled phase 2/3 study aims to evaluate the efficacy, safety and tolerability of BMS-986089 administered to 6- to 11-year-old street boys. with DMD. This molecule could promote muscle growth by inhibiting myostatin, a protein that limits this growth.
Further details on Wave-OLE here
Further details on Anti-myostatin there
